WO2022134657A1 - 一类抗前列腺癌的瑞香烷型二萜及其制备方法 - Google Patents

一类抗前列腺癌的瑞香烷型二萜及其制备方法 Download PDF

Info

Publication number
WO2022134657A1
WO2022134657A1 PCT/CN2021/116955 CN2021116955W WO2022134657A1 WO 2022134657 A1 WO2022134657 A1 WO 2022134657A1 CN 2021116955 W CN2021116955 W CN 2021116955W WO 2022134657 A1 WO2022134657 A1 WO 2022134657A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
prostate cancer
daphne
type diterpene
hydrogen
Prior art date
Application number
PCT/CN2021/116955
Other languages
English (en)
French (fr)
Inventor
尹胜
严雪龙
王军舰
黄家洛
唐贵华
Original Assignee
中山大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中山大学 filed Critical 中山大学
Publication of WO2022134657A1 publication Critical patent/WO2022134657A1/zh
Priority to US18/157,529 priority Critical patent/US20230159551A1/en

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/32—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by aldehydo- or ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems

Definitions

  • the present invention relates to a natural compound and its preparation method and application, in particular to a class of daphne-type diterpene compounds, its preparation method and its application in the preparation of anti-castration-resistant prostate cancer drugs.
  • Prostate cancer is a high incidence of malignant tumors in middle-aged and elderly people. According to the latest cancer statistics of the American Cancer Society (ACS) in 2020, the incidence of prostate cancer in the United States ranks first among malignant tumors, and the mortality rate ranks second. In our country, with the change of living standards and pace of life, the incidence of prostate cancer has risen year by year.
  • ACS American Cancer Society
  • Castration-resistant prostate cancer is closely related to the abnormally activated androgen receptor (AR) signaling pathway.
  • AR abnormally activated androgen receptor
  • Daphneaceae plants are rich in novel daphne-type diterpenes. They are complex molecular structures with a 5/7/6 tricyclic carbon skeleton, containing multiple chiral centers, usually containing chiral hydroxyl groups at positions such as C3, C4, C5, C9, C13, C14, and C20; among them, many compounds A specific orthoester structure is formed between the chiral hydroxyl groups at C9, C13, and C14 positions.
  • Daphne-type diterpenes have anti-HIV, anti-leukemia, anti-tumor, neuroprotective, insecticidal, cytotoxic and other activities. And our study found that this diterpenoid has a very significant inhibitory activity on prostate cancer cells, which is stronger than the existing clinical targeted drug enzalutamide at the cellular and animal levels. However, the in-depth pharmacodynamics, structure-activity relationship and mechanism of action of these diterpenoids against prostate cancer are still lacking.
  • the first aspect of the present invention provides: the application of a daphnetane-type diterpenoid compound in the preparation of a castration-resistant prostate cancer treatment or combination therapy drug, the general formula of the daphne-type diterpenoid compound is as formula I or formula II shown:
  • R 1 is selected from hydrogen or hydroxyl
  • R 2 is selected from hydrogen, hydroxyl, carbonyl, benzoyl or acetyl
  • R is selected from hydrogen, hydroxyl, acetyl, isovaleryl, crotonyl or benzoyl;
  • R 4 is selected from hydrogen, hydroxyl, acetyl, isobutyryl, 2-thiophenoyl, benzoyl or palmitoyl;
  • R7 is selected from methyl, phenyl, nonanyl, (1E,3E)-nonadienyl, (1E,3Z)-nonadienyl or (1E,3E,5E)-nonanetri alkenyl;
  • R 7 is selected from hydrogen, benzoyl, acetyl, decadienoyl, (2E,4E)-decadienoyl, (2E,4Z)-decadienoyl or (2E,4E,6E)- Decatrienoyl;
  • R 8 is selected from hydrogen or hydroxyl
  • R 9 is selected from hydrogen, hydroxy, acetyl, benzoyl, isobutyryl, butyryl or propionyl.
  • the Daphne-type diterpene compound is selected from:
  • the Daphne-type diterpene compound is selected from YH-6, YH-11, YH-16, YH-17, YH-22, YH-35, YH-36, YH-47, YH-48 , at least one of YH-49, YH-50, YH-52 and YH-53.
  • the Daphne-type diterpene compounds also include pharmaceutically acceptable derivatives thereof.
  • the pharmaceutically acceptable derivative is a salt thereof.
  • a second aspect of the present invention provides:
  • Daphne-type diterpene compounds and pharmaceutical derivatives thereof, the Daphne-type diterpene compounds are described in the first aspect of the present invention.
  • the Daphne-type diterpene compound is selected from the compounds of claim 2 YH-8, YH-9, YH-10, YH-19, YH-20, YH-21, YH-24, YH -25, YH-26, YH-30, YH-33, YH-34, YH-37, YH-38, YH-39, YH-45, YH-46, YH-47, YH-48, YH-49 , YH-50, YH-52, YH-53, YH-56, YH-57, YH-60, YH-61.
  • a third aspect of the present invention provides:
  • a composition for the treatment or adjuvant treatment of castration-resistant prostate cancer comprises the daphne-type diterpene compound and acceptable pharmaceutically acceptable derivatives thereof according to the first aspect of the present invention. at least one.
  • the pharmaceutically acceptable derivative is a salt thereof.
  • the daphne-type diterpene compound is selected from compounds YH-6, YH-11, YH-16, YH-17, YH-22, YH-35, YH-36, YH-8, YH- 9.
  • YH-10 YH-19, YH-20, YH-21, YH-24, YH-25, YH-26, YH-30, YH-33, YH-34, YH-37, YH-38, YH-39, YH-45, YH-46, YH-47, YH-48, YH-49, YH-50, YH-52, YH-53, YH-56, YH-57, YH-60, YH- 61 and acceptable pharmaceutically acceptable derivatives thereof.
  • the composition further includes at least one compound having a therapeutic effect on prostate cancer, preferably, the compound having a therapeutic effect on prostate cancer is enzalutamide, abiraterone, cyclophosphamide, Doxorubicin, Docetaxel, Mitoxantrone.
  • a fourth aspect of the present invention provides:
  • a method of treating or adjuvant therapy for castration-resistant prostate cancer comprising:
  • a therapeutic amount of a daphnetane-type diterpene compound or a pharmaceutically acceptable salt, solvate, or co-crystal thereof is administered to a patient, and the daphne-type diterpene compound is as described in the first aspect of the present invention.
  • it also includes administering to the patient at least one compound having a therapeutic effect on prostate cancer, preferably, the compound having a therapeutic effect on prostate cancer is enzalutamide, abiraterone, cyclophosphamide, adriamycin Docetaxel, Docetaxel, Mitoxantrone.
  • Daphne-type diterpenoids was isolated or synthesized for the first time. These compounds can significantly inhibit the proliferation of various prostate cancer cells, especially the compound YH-52 has stronger activity than the existing clinical targeted drug enzalutamide at the cellular level and animal level, and it is used in combination with enzalutamide It has a strong synergistic effect and is expected to become a candidate drug for the treatment of castration-resistant prostate cancer.
  • Fig. 1 is the flow chart of Chinese daisy extraction and separation
  • Fig. 2 is the therapeutic effect of compound YH-52 oral administration on prostate cancer 22RV1 xenograft mice;
  • Figure 3 shows the therapeutic effect of YH-52 and enzalutamide combined with intraperitoneal injection on prostate cancer 22RV1 xenograft mice.
  • the inventor isolated and obtained 34 natural daphne-type diterpenes from Daphneaceae plants, and obtained 30 derivatives by structural modification of some compounds.
  • the obtained series of diterpenes were tested against prostate cancer cells, and a series of compounds with significant inhibitory activity against the tumor cells were found, and the effect was stronger than the existing clinical targeted drug enzalutamide.
  • One of the new compounds is expected to as a candidate drug for the treatment of castration-resistant prostate cancer.
  • the technical solutions of the present invention are further described below in conjunction with the embodiments.
  • the reagents, equipment and methods used in the present invention are conventional commercially available reagents, equipment and methods commonly used in the technical field.
  • the Daphneaceae plants (taking daphnia as an example) are studied.
  • NMR spectra were recorded with a Bruker AM-400/500 spectrometer, TMS internal standard.
  • Column chromatography silica gel 300-400 mesh: Qingdao Ocean Chemical Factory; GF 254 silica gel thin-layer chromatography prefabricated plate: Qingdao Ocean Chemical Factory; MCI filler (CHP20P, 75-150 ⁇ m): Japan Mitsubishi Company; Sephadex (Sephadex) LH-20): GE company of the United States; ODS filler (12nm, S-50 ⁇ m): YMC company of Japan; other solvents and reagents: analytical grade (AR), Tianjin Best Chemical Co., Ltd.
  • AR analytical grade
  • Example 1 Compound YH-30 was obtained by semi-preparative HPLC purification, and its structure and data were as follows:
  • Example 2 Compound YH-60 was obtained by semi-preparative HPLC separation and purification, and its structure and data were as follows:
  • the raw material compounds used in the following examples are YH-6, YH-11, YH-16 and YH-22, and their structures are as follows:
  • All prostate cancer cells were cultured in RPMI-1640 medium containing 10% calf serum, 100 units per milliliter of penicillin and 100 g/mL streptomycin, and were cultured in a 37°C incubator with a saturated humidity of 5% carbon dioxide.
  • the cells in the logarithmic growth phase were cultured in a 96-well plate for 24 hours (5 ⁇ 10 3 cells/well), then treated with different concentrations of the compounds to be tested, cultured by MTT method for 4 hours, centrifuged to discard the supernatant, and added
  • the MTT crystals were dissolved in DMSO, and the absorbance was measured at a wavelength of 570 nm by an enzyme-linked immunosorbent assay.
  • the cytotoxic activity of the test compound against cancer cells is expressed by IC50 .
  • the modification of the 1'-alkene side chain of this class of compounds has unpredictable effects on the activity, but in general, the compounds with the 1'-alkene side chain are more cytotoxic, such as compounds YH-16 and YH-22 cytotoxic Stronger than YH-11 and YH-6.
  • YH-52 was selected as a candidate compound for in vivo pharmacodynamic evaluation in animals.
  • ENZ positive drug enzalutamide
  • DOX positive drug doxorubicin
  • NA less active, not tested.
  • 22RV1 cells were expanded. In order to ensure the success rate of tumor bearing, the cell state should be adjusted to the best state. When the number of cells was sufficient, cells were digested and washed twice with PBS buffer to remove fetal bovine serum (FBS) in the medium to reduce immune rejection. Cells were adjusted to 3000*10 4 /mL after hemocytometer counting. 22Rv1 human prostate cancer cells (100 ⁇ L) were then injected subcutaneously into 4-5 week old nod-scid severely immunodeficient male mice.
  • FBS fetal bovine serum
  • mice When the tumor grows to a volume of about 100 mm 3 , the mice are randomly divided into 3 groups (the average tumor volume is the same).
  • the mice in the drug-adding group are orally gavaged with 0.5 mg/kg and 2 mg/kg of compound YH-52 every day, and the control group.
  • the same volume of normal saline with DMSO content was administered.
  • the body weight of the mice and the length and width of the tumor were measured and recorded every 3 days.
  • the time of continuous administration is shown in Figure 2.
  • the subcutaneous tumor was taken out and photographed.
  • the compound YH-52 can significantly inhibit the growth of tumor in mice at doses of 0.5 mg/kg and 2 mg/kg orally.
  • YH-52 intraperitoneal injection dose 0.1mg/kg
  • intraperitoneal injection has obvious synergistic effect (Figure 3).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了一类抗前列腺癌的瑞香烷型二萜及其制备方法。发明人研究发现式（I）式（II）所示瑞香烷型二萜化合物可以显著抑制多种前列腺癌细胞的增殖，一些化合物在细胞水平和动物水平活性均强于现有临床靶向药物恩杂鲁胺，且与恩杂鲁胺联合用药后具有较强的协同效果，有望成为治疗或辅助治疗去势抵抗性前列腺癌的候选药物。

Description

一类抗前列腺癌的瑞香烷型二萜及其制备方法 技术领域
本发明涉及一种天然化合物及其制备方法和应用，特别涉及一类瑞香烷型二萜化合物及其制备方法和在制备抗去势抵抗性前列腺癌药物方面的应用。
背景技术
前列腺癌是中老年人高发恶性肿瘤，据美国癌症协会(ACS)2020年最新癌症统计数据，美国前列腺癌发病率在恶性肿瘤中高居首位，死亡率排第二位。在我国，随着生活水平和生活节奏的改变前列腺癌的发病率也逐年飙升。
前列腺癌后期演变为去势抵抗性前列腺癌，对激素治疗无效而发生转移，是导致病人死亡的重要因素。去势抵抗性前列腺癌与异常激活的雄激素受体(AR)信号通路密切相关，分别在2010年和2011年上市的抗雄激素药物恩杂鲁胺和阿比特龙能显著提高患者生存期，但由于获得性耐药，在治疗后期收效甚微。因此，开发新型抗去势抵抗性前列腺癌的新药具有重要的研究意义和应用价值。
天然产物因具有结构多样性和良好的生物兼容性是新药研发的重要来源。文献调研显示瑞香科植物中富含结构新颖的瑞香烷型二萜。它们是具有5/7/6三环碳骨架的复杂分子结构，含有多个手性中心，通常在C3、C4、C5、C9、C13、C14、C20等位置含有手性羟基；其中，诸多化合物在C9、C13、C14位置的手性羟基之间形成特定的原酸酯结构。
技术问题
瑞香烷型二萜具有抗HIV、抗白血病、抗肿瘤、神经保护、杀虫、细胞毒等活性。并且我们研究发现该类二萜对前列腺癌细胞具有非常显著的抑制活性，在细胞水平和动物水平强于现有临床靶向药物恩杂鲁胺。然而，该类二萜抗前列腺癌的深入药效学、构效关系及作用机制研究尚且匮乏。
技术解决方案
本发明的第一个方面，提供：瑞香烷型二萜化合物在制备去势抵抗性前列腺癌治疗或联合治疗药物中的应用，所述瑞香烷型二萜化合物的通式如式Ⅰ或式II所示：
Figure PCTCN2021116955-appb-000001
式I和式II中：C-1和C-2之间为双键或不为双键；C-6和C-7之间为双键或不为双键；C-15和C-16之间为双键或不为双键；
R 1选自氢或羟基；
R 2选自氢、羟基、羰基、苯甲酰基或乙酰基；
R 3选自氢、羟基、乙酰基、异戊酰基、巴豆酰基或苯甲酰基；
R 4选自氢、羟基、乙酰基、异丁酰基、2-噻吩甲酰基、苯甲酰基或棕榈酰基；
R 5选自羟基、氟、氯、溴、碘，与R 6形成三元环氧或与R 6消除形成C6＝C7双键；
R 6选自氢、羟基、氟、氯、溴、碘，与R 5形成三元环氧或与R 5消除形成C6＝C7双键；
式I中：R 7选自甲基、苯基、壬烷基、(1E，3E)-壬二烯基、(1E，3Z)-壬二烯基或(1E，3E，5E)-壬三烯基；
式II中：R 7选自氢、苯甲酰基、乙酰基、癸酰基、(2E，4E)-癸二烯酰基、(2E，4Z)-癸二烯酰基或(2E，4E，6E)-癸三烯酰基；
R 8选自氢或羟基；
R 9选自氢、羟基、乙酰基、苯甲酰基、异丁酰基、丁酰基或丙酰基。
在一些实例中，所述瑞香烷型二萜化合物选自：
Figure PCTCN2021116955-appb-000002
在一些实例中，所述瑞香烷型二萜化合物选自YH-6、YH-11、YH-16、YH-17、YH-22、YH-35、YH-36、YH-47、YH-48、YH-49、YH-50、YH-52及YH-53中的至少一种。
在一些实例中，所述瑞香烷型二萜化合物还包括其药学上可接受的衍生物。
在一些实例中，所述药学上可接受的衍生物为其盐。
本发明的第二个方面，提供：
瑞香烷型二萜化合物及其药用衍生物，所述瑞香烷型二萜化合物如本发明第一个方面所述。
在一些实例中，所述瑞香烷型二萜化合物选自权利要求2中的化合物YH-8、YH-9、YH-10、 YH-19、YH-20、YH-21、YH-24、YH-25、YH-26、YH-30、YH-33、YH-34、YH-37、YH-38、YH-39、YH-45、YH-46、YH-47、YH-48、YH-49、YH-50、YH-52、YH-53、YH-56、YH-57、YH-60、YH-61。
本发明的第三个方面，提供：
一种治疗或辅助治疗去势抵抗性前列腺癌的组合物，所述组合物的活性成分包括本发明第一个方面所述的瑞香烷型二萜化合物及其可接受的药用衍生物中的至少一种。
在一些实例中，所述药学上可接受的衍生物为其盐。
在一些实例中，所述瑞香烷型二萜化合物选自化合物YH-6、YH-11、YH-16、YH-17、YH-22、YH-35、YH-36、YH-8、YH-9、YH-10、YH-19、YH-20、YH-21、YH-24、YH-25、YH-26、YH-30、YH-33、YH-34、YH-37、YH-38、YH-39、YH-45、YH-46、YH-47、YH-48、YH-49、YH-50、YH-52、YH-53、YH-56、YH-57、YH-60、YH-61及其可接受的药用衍生物。
在一些实例中，所述组合物还包括至少一种对前列腺癌有治疗作用的化合物，优选的，所述对前列腺癌有治疗作用的化合物为恩杂鲁胺、阿比特龙、环磷酰胺、阿霉素、多烯紫杉醇、米托蒽醌。
本发明的第四个方面，提供：
一种治疗或辅助治疗去势抵抗性前列腺癌的方法，包括：
检测确认患者患有势抵抗性前列腺癌；
给予患者治疗量的瑞香烷型二萜化合物或其药学上可接受的盐、溶剂化物、共晶，所述瑞香烷型二萜化合物如本发明第一个方面所述。
在一些实例中，还包括给予患者至少一种对前列腺癌有治疗作用的化合物，优选的，所述对前列腺癌有治疗作用的化合物为恩杂鲁胺、阿比特龙、环磷酰胺、阿霉素、多烯紫杉醇、米托蒽醌。
有益效果
首次分离或合成得到了一类瑞香烷型二萜化合物。该类化合物可以显著抑制多种前列腺癌细胞的增殖，特别是化合物YH-52在细胞水平和动物水平活性均强于现有临床靶向药物恩杂鲁胺，且其与恩杂鲁胺联合用药后具有较强的协同效果，有望成为治疗去势抵抗性前列腺癌的候选药物。
附图说明
图1是芫花提取分离流程图；
图2是化合物YH-52口服给药对前列腺癌22RV1异种移植小鼠的治疗作用；
图3是YH-52与恩杂鲁胺联合腹腔注射给药对前列腺癌22RV1异种移植小鼠的治疗作用。
本发明的实施方式
发明人从瑞香科植物芫花中分离得到34个天然瑞香烷型二萜，并对部分化合物进行结构修饰获得30个衍生物。将所得系列二萜进行抗前列腺癌细胞的相关测试，发现了一系列对该肿瘤细胞具有显著抑制活性的化合物，效果强于临床上现有靶向药物恩杂鲁胺，其中1个新化合物有望成为治疗去势抵抗性前列腺癌的候选药物。
下面结合实施例，进一步说明本发明的技术方案。除非特别说明，本发明采用的试剂、设备和方法为本技术领域常规市购的试剂、设备和常规使用的方法。
本发明中对瑞香科植物(以芫花为例)进行研究。
设备及试剂：NMR波谱采用Bruker AM-400/500spectrometer记录，TMS内标。柱色谱硅胶(300～400目)：青岛海洋化工厂；GF 254硅胶薄层色谱预制板：青岛海洋化工厂；MCI填料(CHP20P，75～150μm)：日本Mitsubishi公司；葡聚糖凝胶(Sephadex LH-20)：美国GE公司；ODS填料(12nm，S-50μm)：日本YMC公司；其余溶剂和试剂：分析纯(AR)，天津市百世化工有限公司。
瑞香烷型二萜类化合物的制备
取芫花20kg，粉碎成粗粉。加入3倍体积量的95％乙醇，浸泡1周，抽滤后减压回收乙醇。重复3次以上浸泡提取步骤，最终得到芫花乙醇提取物浸膏1500g，芫花浸膏用1L水分散后，用乙酸乙酯萃取三次。合并乙酸乙酯萃取液，减压浓缩，得到乙酸乙酯萃取物300g。
取上述乙酸乙酯萃取物载于硅胶柱上，用石油醚：乙酸乙酯，二氯甲烷：甲醇进行初步分段，然后用ODS、MCI、凝胶Sephadex LH-20等进一步分离，最后用半制备高效液相色谱手段在(乙腈：水)或(甲醇：水)条件下进一步纯化，得到34个单体化合物，具体分离流程图参考图1。将所得部分瑞香烷型二萜化合物进行结构修饰制备其衍生物。
分离产物的鉴定
实施例1：通过半制备HPLC纯化得到化合物YH-30，其结构和数据如下：
Figure PCTCN2021116955-appb-000003
YH-30:[α] 25 D+7.8(c 0.230,CH 2Cl 2)；UV(MeOH)λ max(logε)232(4.21)nm；ECD(c 3.3×10 -4M,MeCN)λ max(Δε)252(-2.44)nm；IR(KBr)ν max 3445,2925,2856,1705,1632,1451,1401,1379,1301,1268,1108,1070,1026,938,913,863cm -1； 1H NMR(CDCl 3,400MHz)δ H 7.55 (1H,s,H-1),4.20(1H,s,H-5),3.61(1H,s,H-7),3.59(1H,d,J＝2.4Hz,H-8),3.76(1H,m,H-10),2.52(1H,q,J＝7.2Hz,H-11),5.18(1H,s,H-12),4.84(1H,d,J＝2.4Hz,H-14),4.99(2H,s,H-16),1.84(3H,s,H 3-17),1.37(3H,d,J＝7.2Hz,H 3-18),1.76(3H,br s,H 3-19),3.81(1H,d,J＝12.0Hz,H-20a),3.90(1H,d,J＝12.0Hz,H-20b),1′-Me:1.70(3H,s)；12-OBz:7.87(2H,m),7.44(2H,m),7.57(1H,m)； 13C NMR(CDCl 3,100MHz)δ C 160.3(C-1),136.9(C-2),209.4(C-3),72.2(C-4),71.8(C-5),60.7(C-6),64.1(C-7),35.5(C-8),77.8(C-9),47.4(C-10),44.0(C-11),78.9(C-12),83.9(C-13),80.5(C-14),143.0(C-15),113.5(C-16),18.6(C-17),18.3(C-18),9.8(C-19),64.8(C-20),118.9(C-1′),1′-Me:21.5,12-OBz:165.4,129.7,129.4×2,128.6×2,133.3；HRESIMS m/z 541.2070[M+H] +(calcd for C 29H 33O 10 +,541.2068).
实施例2：通过半制备HPLC分离纯化得到化合物YH-60，其结构和数据如下：
Figure PCTCN2021116955-appb-000004
YH-60:[α] 25 D-14.2(c 0.148,CH 2Cl 2)；UV(MeOH)λ max(logε)232(4.50)nm；IR(KBr)ν max 3418,2925,2855,1704,1631,1452,1379,1315,1270,1178,1108,1070,1026,1010,940,915cm -1； 1H NMR(CDCl 3,400MHz)δ H 7.63(1H,s,H-1),4.13(1H,s,H-5),3.36(1H,s,H-7),4.22(1H,d,J＝5.2Hz,H-8),3.51(1H,s,H-10),2.51(1H,m,H-11),5.22(1H,d,J＝2.2Hz,H-12),6.19(1H,d,J＝5.2Hz,H-14),5.04(1H,s,H-16a),5.34(1H,s,H-16b),1.88(3H,s,H 3-17),1.40(3H,d,J＝7.3Hz,H 3-18),1.75(3H,br s,H 3-19),3.34(1H,d,J＝12.3Hz,H-20a),4.00(1H,d,J＝12.3Hz,H-20b),12-OBz:7.97(2H,d,J＝7.4Hz),7.49(2H,m),7.60(1H,m)；14-OBz:8.07(2H,d,J＝7.0Hz),7.28(2H,m),7.60(1H,m)； 13C NMR(CDCl 3,100MHz)δ C 159.6(C-1),137.0(C-2),208.6(C-3),72.4(C-4),69.5(C-5),63.1(C-6),62.8(C-7),40.3(C-8),75.8(C-9),51.0(C-10),42.9(C-11),79.9(C-12),75.2(C-13),73.7(C-14),144.5(C-15),114.9(C-16),19.6(C-17),16.2(C-18),9.9(C-19),65.5(C-20),12-OBz:165.8,129.4,129.6×2,128.6×2,133.3,14-OBz:166.6,129.8,130.0×2,128.4×2,133.4；HRESIMS m/z 619.2168[M-H] -(calcd for C 34H 35O 11 -,619.2185).
衍生物的制备
以下实施例中所用的原料化合物为YH-6，YH-11，YH-16及YH-22，它们的结构如下：
Figure PCTCN2021116955-appb-000005
实施例3：YH-7和YH-8的制备
取化合物YH-6(30mg)溶于2mL吡啶中，在N 2保护下搅拌，然后用注射器打入100μL乙酸酐，50℃加热反应，薄层检测有两个产物，并且原料基本反应完时，加入3mL水使反应停止，之后用EtOAc(5mL)萃取三次，反应产物通过制备薄层(CH 2Cl 2/MeOH,50:1)纯化得YH-7(10mg)与YH-8(15mg)，结构和数据如下：
Figure PCTCN2021116955-appb-000006
YH-7:UV(MeOH)λ max(logε)240(3.70)nm； 1H NMR(400MHz,CDCl 3)δ H 7.72(2H,m),7.49(1H,br s),7.39(3H,m),5.57(1H,s),5.05(2H,s,overlap),5.02(1H,s),4.91(1H,d,J＝2.5Hz),4.80(1H,d,J＝12.0Hz),4.06(1H,m),3.67(1H,d,J＝2.5Hz),3.63(1H,d,J＝12.0Hz),3.53(1H,s),3.07(1H,s),2.37(1H,q,J＝7.3Hz),2.20(3H,s),2.03(6H,s),1.88(3H,s),1.75(1H,br s),1.31(3H,d,J＝7.3Hz)； 13C NMR(100MHz,CDCl 3)δ C 10.0,18.1,18.8,20.6,20.7,21.1,35.4,43.9,47.9,59.5,64.2,66.3,68.4,71.8,78.1,78.3,80.5,84.1,113.5,117.9,126.0,128.0,129.7,135.1,137.1,143.0,158.2,168.8,169.6,170.6,205.6；MS m/z 625.2[M+H] +,659.2[M+Cl] -.
YH-8:[α] D 25+12.0(c 0.47,MeOH),UV(MeOH)λ max(logε)241(4.16)nm；IR(KBr)ν max3469,2929,1738,1698,1234,1082,and 1024cm -1； 1H NMR(CDCl 3,400MHz)δ H 7.57(1H,br s,H-1),4.30(1H,s,H-5),3.51(1H,s,H-7),3.61(1H,d,J＝2.6Hz,H-8),3.96(1H,m,H-10),2.46(1H,q,J＝7.3Hz,H-11),5.07(1H,s,H-12),4.88(1H,d,J＝2.6Hz,H-14),5.04(1H,s,H-16a),5.02(1H,s,H-16b),1.88(3H,s,H 3-17),1.35(3H,d,J＝7.3Hz,H 3-18),1.78(3H,brs,H 3-19),4.83(1H,d,J＝12.0Hz,H-20a),3.92(1H,d,J＝12.0Hz,H-20b).1′-Ph:7.71(2H,m),7.38(2H,m),7.38(1H,m),12-OAc:2.02(3H.s).20-OAc:2.09(3H,s)； 13C NMR(CDCl 3,100MHz)δ C160.1(C-1),136.9(C-2),209.2(C-3),72.2(C-4),69.8(C-5),59.4(C-6),64.0(C-7),35.3(C-8), 78.6(C-9),47.3(C-10),44.0(C-11),78.2(C-12),84.0(C-13),80.7(C-14),143.0(C-15),113.5(C-16),18.8(C-17),18.3(C-18),9.9(C-19),65.7(C-20),117.9(C-1′).1′-Ph:135.2,126.0×2,128.0×2,129.6.12-OAc:169.6,21.1.20-OAc:170.6,20.8；HRESIMS m/z 583.2179[M+H] +(calcd for C 31H 35O 11 +,583.2174).
实施例4：化合物YH-9的制备
取化合物YH-6(20mg)溶于2mL二氯甲烷中，搅拌情况下加入100μL三乙胺(Et 3N)，然后加入苯甲酰氯100μL，反应30分钟，待原料反应完，加入5mL H 2O停止反应，随后用二氯甲烷(3×5mL)萃取，有机相浓缩后用凝胶(Sephadex LH-20,MeOH)和制备薄层(CH 2Cl 2/MeOH,50:1)纯化后得到化合物YH-9(11mg)。其结构和数据如下：
Figure PCTCN2021116955-appb-000007
YH-9:[α] D 25+24(c 0.43,MeOH)；UV(MeOH)λ max(logε)231(3.50)nm；IR(KBr)ν max3465,2925,1721,1274,1240,1082,and 1023cm -1； 1H NMR(CDCl 3,400MHz)δ H 7.58(1H,br s,H-1),4.39(1H,s,H-5),3.59(1H,s,H-7),3.66(1H,d,J＝2.3Hz,H-8),4.01(1H,br s,H-10),2.49(1H,q,J＝7.3Hz,H-11),5.08(1H,s,H-12),4.90(1H,d,J＝2.3Hz,H-14),5.03(1H,s,H-16a),5.05(1H,s,H-16b),1.88(3H,s,H 3-17),1.37(3H,d,J＝7.3Hz,H 3-18),1.79(3H,br s,H 3-19),5.13(1H,d,J＝11.9Hz,H-20a),4.10(1H,d,J＝11.9Hz,H-20b).1′-Ph:7.71(2H,m),7.38(2H,m),7.38(1H,m).12-OAc:2.02(3H.s).20-OBz:8.05(2H,d,J＝7.7Hz),7.43(2H,t,J＝7.7Hz),7.56(1H,m)； 13C NMR(CDCl 3,100MHz)δ C 160.1(C-1),136.9(C-2),209.2(C-3),72.3(C-4),69.8(C-5),59.7(C-6),64.2(C-7),35.3(C-8),78.6(C-9),47.3(C-10),44.0(C-11),78.3(C-12),84.1(C-13),80.7(C-14),143.0(C-15),113.5(C-16),18.8(C-17),18.3(C-18),9.9(C-19),66.6(C-20),117.9(C-1′).1′-Ph:135.2,126.0×2,128.0×2,129.6.12-OAc:169.6,21.1.20-OBz:166.2,129.8,129.7×2,128.4×2,133.2；ESIMS m/z 645.2[M+H] +,679.2[M+Cl] -；HRESIMS m/z643.2184[M-H] -(calcd for C 36H 35O 11 -,643.2185).
实施例5：化合物YH-10的制备
取化合物YH-6(20mg)溶于无水吡啶中，抽真空加氮气保护，然后用注射器加入100μL2-噻吩甲酰氯(2-Thiophenecarbonyl chloride)，50度加热反应2h，反应完后加入5mL水淬灭，然后用EtOAc(3×5mL)萃取，有机相浓缩后通过制备薄层(CH 2Cl 2/MeOH,50:1)和凝胶(MeOH) 纯化后得化合物YH-10(12mg)。其结构和数据如下：
Figure PCTCN2021116955-appb-000008
YH-10:Colorless oil:[α] D 25+17.1(c 0.23,MeOH)；UV(MeOH)λ max(logε)245(3.94)nm；IR(KBr)ν max 3476,2924,1706,1257,1230,1081,and 750cm -1； 1H NMR(CDCl 3,400MHz)δ H7.57(1H,br s,H-1),4.36(1H,s,H-5),3.57(1H,s,H-7),3.64(1H,d,J＝2.5Hz,H-8),3.98(1H,m,H-10),2.48(1H,q,J＝7.2Hz,H-11),5.07(1H,s,H-12),4.90(1H,d,J＝2.5Hz,H-14),5.05(1H,s,H-16a),5.02(1H,s,H-16b),1.88(3H,s,H 3-17),1.36(3H,d,J＝7.2Hz,H 3-18),1.79(3H,br s,H 3-19),5.12(1H,d,J＝11.9Hz,H-20a),4.05(1H,d,J＝11.9Hz,H-20b).1′-Ph:7.71(2H,m),7.38(2H,m),7.38(1H,m).12-OAc:2.02(3H.s).2-thenoyl:7.82(1H,dd,J＝3.7,1.1Hz),7.09(1H,dd,J＝4.8,3.9Hz),7.55(1H,dd,J＝4.8,1.1Hz)； 13C NMR(CDCl 3,100MHz)δ C 160.2(C-1),137.0(C-2),209.2(C-3),72.3(C-4),69.7(C-5),59.7(C-6),64.0(C-7),35.3(C-8),78.6(C-9),47.3(C-10),44.0(C-11),78.2(C-12),84.1(C-13),80.7(C-14),143.0(C-15),113.6(C-16),18.9(C-17),18.3(C-18),10.0(C-19),66.6(C-20),117.9(C-1′).1′-Ph:135.2,126.0×2,128.1×2,129.7.12-OAc:169.7,21.2.2-thenoyl:161.8,133.1,133.9,127.9,132.8；ESIMS m/z 651.2[M+H] +,[M+Cl] -；HRESIMS m/z 651.1858(calcd for C 34H 35O 11S +,651.1855).
实施例6：化合物YH-12和YH-13的制备
取化合物YH-11(30mg)溶于2mL吡啶中，在N 2保护下搅拌，然后用注射器打入100μL乙酸酐，50℃加热反应，薄层检测有两个产物，并且原料基本反应完时，加入3mL水使反应停止，之后用EtOAc(5mL)萃取三次，反应产物通过制备薄层(CH 2Cl 2/MeOH,50:1)纯化得YH-12(13mg)与YH-13(10mg)，结构和数据如下：
Figure PCTCN2021116955-appb-000009
YH-12:[α] D 25+63.3(c 0.33,MeOH)；UV(MeOH)λ max(logε)231(3.99)nm；IR(KBr)ν max 3445,2925,1710,1268,1080,and 713cm -1； 1H NMR(CDCl 3,400MHz)δ H 7.50(1H,br s,H-1),5.55(1H,s,H-5),3.59(1H,s,H-7),3.78(1H,d,J＝2.5Hz,H-8),4.08(1H,m,H-10),2.55(1H,q,J＝7.2Hz,H-11),5.28(1H,s,H-12),5.05(1H,d,J＝2.5Hz,H-14),5.09(1H,s,H-16a),5.04(1H,s,H-16b),1.92(3H,s,H 3-17),1.40(3H,d,J＝7.2Hz,H 3-18),1.74(3H,br s,H 3-19),4.79(1H,d,J＝12.0Hz,H-20a),3.64(1H,d,J＝12.0Hz,H-20b).1′-Ph:7.75(2H,m),7.40(2H,m),7.40(1H,m).12-OBz:7.94(2H,m),7.48(2H,m),7.61(1H,m).5-OAc:2.14(3H,s).20-OAc:2.03(3H,s)； 13C NMR(CDCl 3,100MHz)δ C 158.0(C-1),137.2(C-2),205.4(C-3),71.7(C-4),68.4(C-5),59.6(C-6),64.2(C-7),35.9(C-8),78.4(C-9),47.9(C-10),44.0(C-11),78.9(C-12),84.3(C-13),80.6(C-14),142.9(C-15),113.8(C-16),18.9(C-17),18.2(C-18),10.0(C-19),66.4(C-20),118.0(C-1′).1′-Ph:135.1,126.0×2,128.1×2,129.7.12-OBz:165.4,129.7,129.5×2,128.6×2,133.4.5-OAc:168.8,20.7.20-OAc:170.6,20.3；ESIMS m/z 687.3[M+H] +；HRESIMS m/z 687.2420[M+H] +(calcd for C 38H 39O 12 +,687.2436).
YH-13:white powder；[α] D 25+50.2(c 0.43,MeOH)；UV(MeOH)λ max(logε)232(4.02)nm；IR(KBr)ν max 3446,2925,1908,1451,1365,1267,1241,978,713cm -1； 1H NMR(CDCl 3,400MHz)δ H 7.59(1H,br s,H-1),4.28(1H,d,J＝2.4Hz,H-5),3.59(1H,s,H-7),3.73(1H,d,J＝2.5Hz,H-8),3.98(1H,m,H-10),2.64(1H,q,J＝7.3Hz,H-11),5.32(1H,s,H-12),5.01(1H,d,J＝2.5Hz,H-14),5.08(1H,s,H-16a),5.03(1H,s,H-16b),1.92(3H,s,H 3-17),1.45(3H,d,J＝7.3Hz,H 3-18),1.77(3H,br s,H 3-19),4.84(1H,d,J＝12.0Hz,H-20a),3.92(1H,d,J＝12.0Hz,H-20b).1′-Ph:7.75(2H,m),7.40(2H,m),7.40(1H,m).12-OBz:7.92(2H,m),7.47(2H,m),7.59(1H,m).20-OAc:2.09(3H,s)； 13C NMR(CDCl 3,100MHz)δ C 160.1(C-1),136.9(C-2),209.2(C-3),72.1(C-4),69.8(C-5),59.4(C-6),64.1(C-7),35.7(C-8),78.6(C-9),47.3(C-10),44.1(C-11),78.9(C-12),84.2(C-13),80.7(C-14),142.9(C-15),113.8(C-16),18.9(C-17),18.4(C-18),9.9(C-19),65.8(C-20),118.0(C-1′).1′-Ph:135.1,126.0×2,128.1×2,129.7.12-OBz:165.4,129.7,129.5×2,128.6×2,133.4.20-OAc:170.6,20.9；ESIMS m/z 645.3[M+H] +；HRESIMS m/z 645.2339[M+H] +(calcd for C 36H 37O 11 +,645.2330).
实施例7：化合物YH-25的制备
取化合物YH-22(23mg)，参照实施例4中的方法制备，所得产物经过凝胶(Sephadex LH-20,MeOH)和制备薄层(CH 2Cl 2/MeOH,100:1)纯化后得YH-25(15mg)。其结构和数据如下：
Figure PCTCN2021116955-appb-000010
YH-25:Colorless oil；[α] D 25+28.5(c 0.067,MeOH)；UV(MeOH)λ max(logε)230(4.50)nm；IR(KBr)ν max 3459,2926,1719,1273,1230,1026,and 711cm -1； 1H NMR(CDCl 3,400MHz)δ H7.57(1H,m,H-1),4.37(1H,s,H-5),3.52(1H,s,H-7),3.57(1H,d,J＝2.5Hz,H-8),3.91(1H,m,H-10),2.40(1H,q,J＝7.2Hz,H-11),4.99(1H,s,H-12),4.76(1H,d,J＝2.5Hz,H-14),5.01(1H,s,H-16a),4.97(1H,s,H-16b),1.84(3H,s,H 3-17),1.30(3H,d,J＝7.2Hz,H-18),1.78(3H,br s,H 3-19),5.12(1H,d,J＝11.9Hz,H-20a),4.07(1H,d,J＝11.9Hz,H-20b),5.64(1H,d,J＝15.5Hz,H-2′),6.66(1H,dd,J＝15.5,10.6Hz,H-3′),6.03(1H,dd,J＝15.0,10.6Hz,H-4′),5.85(1H,dd,J＝15.0,7.4Hz,H-5′),2.08(2H,m,H 2-6′),1.37(2H,m,H 2-7′),1.26(2H,m,H 2-8′),1.26(2H,m,H 2-9′),0.87(3H,t,J＝6.9Hz,H-10′).12-OAc:1.99(3H.s).20-OBz:8.04(2H,d,J＝7.3Hz),7.44(2H,m,),7.56(1H,m)； 13C NMR(CDCl 3,100MHz)δ C 160.2(C-1),136.9(C-2),209.2(C-3),72.3(C-4),69.7(C-5),59.7(C-6),64.1(C-7),35.2(C-8),78.1(C-9),47.3(C-10),43.9(C-11),78.2(C-12),83.6(C-13),80.3(C-14),143.1(C-15),113.3(C-16),18.7(C-17),18.2(C-18),9.9(C-19),66.6(C-20),117.1(C-1′),122.2(C-2′),135.0(C-3′),128.5(C-4′),139.3(C-5′),32.6(C-6′),28.7(C-7′),31.3(C-8′),22.5(C-9′),14.0(C-10′).12-OAc:169.7,21.1.20-OBz:166.2,129.7,129.7×2,128.4×2,133.1；ESIMS m/z 691.3[M+H] +,725.2[M+Cl] -；HRESIMS m/z 689.2962[M-H] -(calcd for C 39H 45O 11,689.2967).
实施例8：化合物YH-33的制备
取化合物YH-22(30mg)溶于3mL二氯甲烷中，加入10mg Grubbs二代催化剂，抽真空加氮气保护，用注射器加入200μL苯乙烯，然后在40℃加热搅拌反应1小时。过滤除掉催化剂，滤液浓缩后用HPLC(MeCN/H 2O,75％,3mL/min)纯化得化合物YH-33(15mg,t R＝10min)。其结构和数据如下：
Figure PCTCN2021116955-appb-000011
YH-33:[α] D 25+4.2(c 0.33,MeOH)；UV(MeOH)λ max(logε)286(4.26)nm； 1H NMR (CDCl 3,400MHz)δ H 7.59(1H,br s,H-1),4.27(1H,s,H-5),3.57(1H,s,H-7),3.53(1H,d,J＝2.5Hz,H-8),3.85(1H,m,H-10),2.39(1H,q,J＝7.3Hz,H-11),5.00(1H,s,H-12),4.79(1H,d,J＝2.5Hz,H-14),5.03(1H,br s,H-16a),4.97(1H,br s,H-16b),1.85(3H,s,H 3-17),1.31(3H,d,J＝7.3Hz,H 3-18),1.80(3H,br s,H 3-19),3.94(1H,d,J＝12.4Hz,H-20a),3.81(1H,d,J＝12.4Hz,H-20b),5.88(1H,d,J＝14.9Hz,H-2′),6.86(1H,dd,J＝14.9,10.0Hz,H-3′),6.77(1H,dd,J＝15.1,10.0Hz,H-4′),6.69(1H,d,J＝15.1Hz,H-5′),7.40(2H,m,H-7′/H-11′),7.32(1H,dd,J＝7.5,7.5Hz,H-8′/H-10′),7.26(1H,m,H-9′)；12-OAc:2.00(3H,s)； 13C NMR(CDCl 3,100MHz)δ C160.3(C-1),136.9(C-2),209.4(C-3),72.2(C-4),71.9(C-5),60.5(C-6),64.2(C-7),35.4(C-8),78.3(C-9),47.4(C-10),44.0(C-11),78.2(C-12),83.8(C-13),80.5(C-14),143.0(C-15),113.4(C-16),18.7(C-17),18.3(C-18),9.9(C-19),65.1(C-20),116.8(C-1′),124.9(C-2′),134.8(C-3′),127.0(C-4′),136.0(C-5′),136.7(C-6′),126.7(C-7′/C-11′),128.6(C-8′/10′),128.1(C-9′),12-OAc:169.7,21.2；HRESIMS m/z 615.2206[M+Na] +(calcd for,C 33H 36O 10Na +,615.2201)and 627.1993[M+Cl] -(calcd for C 33H 36O 10Cl -,627.2002).
实施例9：化合物YH-34的制备
取化合物YH-16(30mg)，参照实施例8中的方法进行制备，所得产物经过HPLC(MeCN/H 2O,80％,3mL/min)纯化得化合物YH-34(16mg,t R＝14min)。其结构和数据如下：
Figure PCTCN2021116955-appb-000012
YH-34:[α] D 25+27.8(c 0.13,MeOH)；UV(MeOH)λ max(logε)285(4.24)nm； 1H NMR(CDCl 3,500MHz)δ H 7.61(1H,br s,H-1),4.23(1H,s,H-5),3.66(1H,s,H-7),3.65(1H,d,J＝2.7Hz,H-8),3.87(1H,m,H-10),2.58(1H,q,J＝7.2Hz,H-11),5.24(1H,s,H-12),4.93(1H,d,J＝2.7Hz,H-14),5.04(1H,br s,H-16a),5.02(1H,br s,H-16b),1.89(3H,s,H 3-17),1.41(3H,d,J＝7.2Hz,H 3-18),1.79(3H,br s,H 3-19),3.94(1H,d,J＝12.2Hz,H-20a),3.83(1H,d,J＝12.2Hz,H-20b),5.91(1H,d,J＝15.2Hz,H-2′),6.90(1H,dd,J＝15.2,10.5Hz,H-3′),6.78(1H,dd,J＝15.4,10.5Hz,H-4′),6.73(1H,d,J＝15.4Hz,H-5′),7.41(2H,d,J＝7.6Hz,H-7′/H-11′),7.33(1H,dd,J＝7.6,7.6Hz,H-8′/H-10′),7.26(1H,m,H-9′)；12-OBz:7.90(2H,d,J＝7.6Hz),7.46(2H,dd,J＝7.6,7.6Hz),7.58(1H,dd,J＝7.6,7.6Hz)； 13C NMR(CDCl 3,125MHz)δ C 160.2(C-1),137.0(C-2),209.3(C-3),72.2(C-4),71.8(C-5),60.6(C-6),64.0(C-7),35.8(C-8),78.4(C-9),47.4 (C-10),44.1(C-11),78.9(C-12),84.0(C-13),80.5(C-14),142.9(C-15),113.7(C-16),18.8(C-17),18.3(C-18),9.9(C-19),64.7(C-20),116.9(C-1′),124.8(C-2′),134.8(C-3′),127.0(C-4′),136.1(C-5′),136.7(C-6′),126.7(C-7′/C-11′),128.6(C-8′/10′),128.1(C-9′),12-OBz:129.6,129.5×2,128.7×2,133.3；HRESIMS m/z 689.2147[M+Cl] -(calcd for C 38H 38O 10Cl -,689.2159).
实施例10：化合物YH-37的制备
取化合物YH-22(20mg)溶于3mL甲醇中，加入钯碳催化剂20mg，抽真空后加氢气保护，然后常温下搅拌反应30分钟，过滤除掉钯碳，滤液浓缩后直接用HPLC(MeCN/H 2O,95％,3mL/min)纯化得化合物YH-37(12mg,t R＝14min)。其结构和数据如下：
Figure PCTCN2021116955-appb-000013
YH-37:[α] D 25+87.0(c 0.033,MeOH)；UV(MeOH)λ max(logε)243(4.03)nm；IR(KBr)ν max3465,2925,1744,1698,1230,1027,and 936cm -1； 1H NMR(CDCl 3,400MHz)δ H 7.53(1H,br s,H-1),4.23(1H,s,H-5),3.49(1H,s,H-7),3.34(1H,d,J＝2.4Hz,H-8),3.73(1H,m,H-10),2.30(1H,q,J＝7.3Hz,H-11),4.93(1H,s,H-12),4.44(1H,d,J＝2.4Hz,H-14),1.85(1H,m,H-15),0.91(3H,d,J＝6.9Hz,H 3-16),0.93(3H,d,J＝6.9Hz,H 3-17),1.22(3H,d,J＝7.3Hz,H 3-18),1.78(3H,br s,H 3-19),3.89(1H,d,J＝12.4Hz,H-20a),3.79(1H,d,J＝12.4Hz,H-20b),1.87(2H,m,H 2-2′),1.54(2H,m,H 2-3′),1.27-1.30(8H,m,H-4′-H-7′),1.30(2H,m,H 2-8′),1.26(2H,m,H 2-9′),0.87(3H,t,J＝6.8Hz,H-10′)；12-OAc:2.00(3H,s)； 13C NMR(CDCl 3,100MHz)δ C 160.9(C-1),136.6(C-2),209.7(C-3),72.2(C-4),72.0(C-5),60.4(C-6),64.5(C-7),35.5(C-8),77.2(C-9),47.5(C-10),44.0(C-11),77.5(C-12),83.6(C-13),80.0(C-14),31.3(C-15),16.6(C-16),15.9(C-17),18.1(C-18),9.8(C-19),65.2(C-20),119.9(C-1′),34.8(C-2′),23.4(C-3′),29.6(C-4′),29.5(C-5′),29.5(C-6′),29.3(C-7′),22.7(C-8′),31.8(C-9′),14.1(C-10′)；12-OAc:169.9,21.2；HRESIMS m/z 593.3315[M+H] +(calcd for C 32H 49O 10 +,593.3320).
实施例11：化合物YH-38的制备
取化合物YH-22(20mg)溶于3mL甲醇中，加入钯碳催化剂30mg，抽真空后加氢气保护，50摄氏度搅拌反应30分钟，过滤除掉钯碳，滤液浓缩后直接用HPLC(MeCN/H 2O,95％,3mL/min)纯化得化合物YH-38(9mg,t R＝15min)。其结构和数据如下：
Figure PCTCN2021116955-appb-000014
YH-38:[α] D 25+76.8(c 0.67,MeOH)；UV(MeOH)λ max(logε)202(3.50)nm；IR(KBr)ν max3463,2927,1742,1378,1229,1028,and 940cm -1； 1H NMR(CDCl 3,500MHz)δ H 1.53(1H,m,H-1a),2.28(1H,m,H-1b)2.28(1H,m,H-2),4.07(1H,s,H-5),3.44(1H,s,H-7),3.32(1H,s,H-8),2.84(1H,m,H-10),2.25(1H,m,H-11),5.03(1H,s,H-12),4.40(1H,s,H-14),1.83(1H,m,H-15),0.93(3H,d,J＝6.7Hz,H 3-16),0.93(3H,d,J＝6.7Hz,H 3-17),1.25(3H,d,J＝7.3Hz,H 3-18),1.10(3H,d,J＝5.5Hz,H 3-19),3.87(1H,d,J＝12.2Hz,H-20a),3.75(1H,d,J＝12.2Hz,H-20b),1.84(2H,m,H 2-2′),1.52(2H,m,H 2-3′),1.25-1.31(8H,m,H-4′-H-7′),1.28(2H,m,H 2-8′),1.26(2H,m,H 2-9′),0.87(3H,t,J＝6.7Hz,H-10′)；12-OAc:2.00(3H,s)； 13C NMR(CDCl 3,125MHz)δ C 33.3(C-1),42.8(C-2),220.3(C-3),75.0(C-4),71.1(C-5),60.7(C-6),64.5(C-7),35.5(C-8),77.6(C-9),44.0(C-10),43.5(C-11),76.8(C-12),83.1(C-13),80.3(C-14),31.2(C-15),16.5(C-16),15.9(C-17),18.3(C-18),12.4(C-19),65.4(C-20),120.0(C-1′),34.9(C-2′),23.3(C-3′),29.6(C-4′),29.5(C-5′),29.5(C-6′),29.3(C-7′),22.6(C-8′),31.8(C-9′),14.1(C-10′)；12-OAc:170.0,21.2；HRESIMS m/z 617.3316[M+Na] +(calcd for C 32H 50O 10 +,617.3296).
实施例12：化合物YH-39的制备
取化合物YH-11，参照实施例11中的方法进行制备，所得产物经过HPLC(MeCN/H 2O,70％,3mL/min)纯化得化合物YH-39(10mg,t R＝17min)。其结构和数据如下：
Figure PCTCN2021116955-appb-000015
YH-39:[α] D 25+64.5(c 0.067,MeOH)；UV(MeOH)λ max(logε)230(4.08)nm；IR(KBr)ν max3483,2968,1720,1272,1079,and 1025cm -1； 1H NMR(CDCl 3,400MHz)δ H 2.36(1H,m,H-1α),1.61(1H,m,H-1β),2.25(1H,m,H-2),4.05(1H,s,H-5),3.62(1H,s,H-7),3.59(1H,d,J＝2.4Hz,H-8),3.01(1H,dd,J＝13.2,5.8Hz,H-10),2.54(1H,q,J＝6.9Hz,H-11),5.42(1H,s,H-12),4.74(1H,d,J＝2.4Hz,H-14),2.03(1H,m,H-15),1.04(3H,d,J＝6.7Hz,H 3-16),1.04(3H,d,J＝6.7 Hz,H 3-17),1.46(3H,d,J＝6.9Hz,H 3-18),1.09(3H,d,J＝6.6Hz,H 3-19),3.86(1H,d,J＝12.3Hz,H-20a),3.79(1H,d,J＝12.3Hz,H-20b)；1′-Ph:7.75(2H,m),7.39(2H,m),7.39(1H,m).12-OBz:7.94(2H,d,J＝7.4Hz),7.47(2H,dd,J＝7.4,7.4Hz),7.59(1H,dd,J＝7.4,7.4Hz)； 13C NMR(CDCl 3,100MHz)δ C 33.4(C-1),42.8(C-2),220.1(C-3),74.9(C-4),71.2(C-5),60.7(C-6),64.4(C-7),36.1(C-8),78.9(C-9),44.1(C-10),43.8(C-11),77.3(C-12),84.1(C-13),81.0(C-14),31.6(C-15),16.7(C-16),16.2(C-17),18.6(C-18),12.4(C-19),65.1(C-20),118.1(C-1′).1′-Ph:135.7,125.9×2,128.0×2,129.5.12-OBz:165.6,129.8,129.5×2,128.6×2,133.3；HRESIMS m/z605.2407[M-H] -(calcd for C 34H 37O 10 －,605.2392).
实施例13：YH-47和YH-48的制备
取化合物YH-6(30mg)溶于2mL四氢呋喃(THF)，搅拌的情况下加入200μL浓盐酸，反应20min左右，加入10mL水使反应停止，然后加入EtOAc(3×10mL)萃取。反应产物经过凝胶(MeOH)和制备薄层(CH 2Cl 2/MeOH,40:1)得化合物YH-47(13mg)和YH-48(10mg)。其结构和数据如下：
Figure PCTCN2021116955-appb-000016
YH-47:[α] D 25+10.5(c 0.13,MeOH)；UV(MeOH)λ max(logε)241(3.70)nm；IR(KBr)ν max3451,2925,1740,1691,1230,1078,and 697cm -1； 1H NMR(CDCl 3,400MHz)δ H 7.61(1H,br s,H-1),4.38(1H,s,H-5),4.74(1H,s,H-7),3.60(1H,d,J＝2.4Hz,H-8),4.04(1H,m,H-10),2.85(1H,q,J＝7.3Hz,H-11),5.03(1H,s,H-12),4.96(1H,d,J＝2.4Hz,H-14),5.03(1H,s,H-16a),5.06(1H,s,H-16b),1.87(3H,s,H 3-17),1.35(3H,d,J＝7.3Hz,H 3-18),1.81(3H,br s,H 3-19),4.01(1H,d,J＝11.3Hz,H-20a),4.16(1H,d,J＝11.3Hz,H-20b).1′-Ph:7.64(2H,m),7.41(2H,m),7.40(1H,m).12-OAc:1.98(3H.s)； 13C NMR(CDCl 3,100MHz)δ C 158.6(C-1),136.7(C-2),208.6(C-3),75.2(C-4),70.9(C-5),76.9(C-6),81.4(C-7),36.2(C-8),78.9(C-9),49.9(C-10),43.5(C-11),77.7(C-12),84.7(C-13),82.7(C-14),142.4(C-15),113.9(C-16),18.7(C-17),17.8(C-18),9.9(C-19),68.8(C-20),117.7(C-1′).1′-Ph:134.6,125.8×2,128.2×2,130.0.12-OAc:169.5,20.9；HRESIMS m/z 575.1685[M-H] -(calcd.for C 29H 32O 10Cl -,575.1689).
YH-48:[α] D 25+15(c 0.1,MeOH)；UV(MeOH)λ max(logε)241(3.70)nm；IR(KBr)ν max 3451,2925,1740,1691,1230,1078,and 697cm -1； 1H NMR(CDCl 3,400MHz)δ H 7.59(1H,br s,H-1),3.96(1H,s,H-5),4.89(1H,d,J＝9.8Hz,H-7),3.06(1H,m,H-8),3.07(1H,m,H-10),2.85(1H,q,J＝7.2Hz,H-11),5.02(1H,s,H-12),5.37(1H,d,J＝2.4Hz,H-14),5.01(1H,s,H-16a),5.03(1H,s,H-16b),1.85(3H,s,H 3-17),1.33(3H,d,J＝7.2Hz,H 3-18),1.80(3H,br s,H 3-19),4.06(1H,d,J＝10.4Hz,H-20a),4.46(1H,d,J＝10.4Hz,H-20b).1′-Ph:7.67(2H,m),7.39(2H,m),7.39(1H,m).12-OAc:2.03(3H.s)； 13C NMR(CDCl 3,100MHz)δ C 158.9(C-1),137.6(C-2),208.5(C-3),73.3(C-4),81.7(C-5),79.0(C-6),66.9(C-7),36.8(C-8),78.4(C-9),50.6(C-10),42.8(C-11),77.9(C-12),84.2(C-13),79.1(C-14),142.8(C-15),113.7(C-16),18.8(C-17),18.1(C-18),10.0(C-19),61.8(C-20),117.4(C-1′).1′-Ph:134.8,125.9×2,128.1×2,129.8.12-OAc:169.7,21.0；HRESIMS m/z 575.1681[M-H] -(calcd.for C 29H 32O 10Cl -,575.1689).
实施例14:YH-49和YH-50的制备
取化合物YH-11(40mg)，用实施例13中相同的方法制备后经制备薄层(CH 2Cl 2/MeOH,50:1)纯化得化合物YH-49(20mg)和YH-50(12mg)。其结构和数据如下：
Figure PCTCN2021116955-appb-000017
YH-49:[α] D 25+23.6(c 0.46,MeOH)；UV(MeOH)λ max(logε)231(4.01)nm；IR(KBr)ν max3450,2924,1721,1268,1079,and 711cm -1； 1H NMR(CDCl 3,400MHz)δ H 7.64(1H,s,H-1),4.40(1H,s,H-5),4.84(1H,s,H-7),3.79(1H,d,J＝2.4Hz,H-8),4.08(1H,m,H-10),2.99(1H,q,J＝7.3Hz,H-11),5.34(1H,s,H-12),5.10(1H,d,J＝2.4Hz,H-14),5.07(1H,s,H-16a),5.03(1H,s,H-16b),1.91(3H,s,H 3-17),1.45(3H,d,J＝7.3Hz,H 3-18),1.81(3H,br s,H 3-19),4.16(1H,d,J＝11.5Hz,H-20a),4.02(1H,d,J＝11.5Hz,H-20b).1′-Ph:7.68(2H,m),7.42(2H,m),7.44(1H,m).12-OBz:7.97(2H,m),7.42(2H,m),7.55(1H,t,J＝7.4Hz)； 13C NMR(CDCl 3,100MHz)δ C158.6(C-1),136.9(C-2),208.6(C-3),75.1(C-4),70.9(C-5),77.0(C-6),81.6(C-7),36.6(C-8),79.1(C-9),49.9(C-10),43.8(C-11),78.0(C-12),85.1(C-13),82.9(C-14),142.4(C-15),114.2(C-16),18.8(C-17),18.0(C-18),9.9(C-19),68.9(C-20),117.9(C-1′).1′-Ph:134.6,125.8×2,128.3×2,130.1.12-OBz:165.1,129.4,129.6×2,128.4×2,133.4；HRESIMS m/z 637.18513[M-H] -(calcd for C 34H 34O 10Cl －,637.18460).
YH-50:[α] D 25+16.7(c 0.35,MeOH)；UV(MeOH)λ max(logε)230(4.10)nm；IR(KBr)ν max3431,2960,1721,1451,1268,and 1075cm -1； 1H NMR(CDCl 3,500MHz)δ H 7.62(1H,br s,H-1),3.90(1H,s,H-5),4.90(1H,d,J＝9.9Hz,H-7),3.12(1H,d,J＝9.9Hz,H-8),3.06(1H,br s,H-10),2.99(1H,q,J＝7.2Hz,H-11),5.28(1H,s,H-12),5.51(1H,s,H-14),5.06(1H,s,H-16a),5.01(1H,s,H-16b),1.88(3H,s,H 3-17),1.44(3H,d,J＝7.2Hz,H-18),1.78(3H,br s,H-19),4.33(1H,d,J＝11.1Hz,H-20a),4.06(1H,d,J＝11.1Hz,H-20b).1′-Ph:7.71(2H,d,J＝7.3Hz),7.42(2H,m),7.43(1H,m).12-OBz:7.94(2H,d,7.4),7.47(2H,m),7.59(1H,t,J＝7.4Hz)； 13C NMR(CDCl 3,125MHz)δ C 158.9(C-1),137.6(C-2),208.4(C-3),73.1(C-4),81.8(C-5),78.5(C-6),66.5(C-7),37.1(C-8),78.4(C-9),50.4(C-10),43.0(C-11),78.5(C-12),84.4(C-13),79.2(C-14),142.8(C-15),114.0(C-16),18.9(C-17),18.3(C-18),10.0(C-19),62.1(C-20),117.5(C-1′).1′-Ph:134.8,125.9×2,128.2×2,130.1.12-OBz:165.0,129.4,129.4×2,128.7×2,133.6；HRESIMS m/z637.18536[M-H] -(calcd for C 34H 34O 10Cl -,637.18460).
实施例15：YH-52和YH-53的制备
取化合物YH-11(100mg)溶于3mL二氯甲烷中，置于-60℃搅拌5分钟后，加入PBr 3(50μL)，薄层检测反应结束后，取出反应液加入5mL水淬灭，加入二氯甲烷萃取(3×5mL)，合并有机层，减压浓缩后通过半制备高效液相(MeCN/H 2O,80:20,3mL/min)纯化后得到YH-52(23mg,t R＝15min)和YH-53(20mg,t R＝12min)。其结构和数据如下：
Figure PCTCN2021116955-appb-000018
YH-52:[α] D 25+56.3(c 0.35,MeOH)；UV(MeOH)λ max(logε)232(3.96)nm；IR(KBr)ν max3445,2923,1720,1692,1268,1078,1008,and 710cm -1； 1H NMR(CDCl 3,400MHz)δ H 7.64(1H,s,H-1),4.27(1H,s,H-5),4.98(1H,s,H-7),3.88(1H,d,J＝2.4Hz,H-8),4.08(1H,s,H-10),3.00(1H,q,J＝7.3Hz,H-11),5.33(1H,s,H-12),5.11(1H,d,J＝2.4Hz,H-14),5.04(1H,s,H-16a),5.08(1H,s,H-16b),1.91(3H,s,H 3-17),1.45(3H,d,J＝7.3Hz,H 3-18),1.81(3H,br s,H 3-19),4.10(1H,d,J＝12.0Hz,H-20a),4.21(1H,m,H-20b),12-OBz:8.01(2H,m),7.39(2H,m),7.55(1H,m)；1′-Ph:7.68(2H,m),7.44(3H,m)； 13C NMR(CDCl 3,100MHz)δ C 158.6(C-1),136.9(C-2),208.7(C-3),75.1(C-4),70.5(C-5),75.8(C-6),82.5(C-7),37.8(C-8),79.2(C-9),50.0 (C-10),43.8(C-11),78.1(C-12),85.1(C-13),82.8(C-14),142.4(C-15),114.2(C-16),18.8(C-17),18.0(C-18),9.9(C-19),69.9(C-20),117.9(C-1′),1′-Ph:134.5,125.8×2,128.4×2,130.1,12-OBz:165.1,129.3,129.8×2,128.3×2,133.4；HRESIMS m/z 705.1309[M+Na] +(calcd for,C 34H 35O 10BrNa +,705.1306).
YH-53:[α] D 25+50.0(c 0.30,MeOH)；UV(MeOH)λ max(logε)232(4.06)nm；IR(KBr)ν max3428,1701,1452,1268,1079,1026,and 712cm -1； 1H NMR(CDCl 3,500MHz)δ H 7.57(1H,s,H-1),3.85(1H,s,H-5),5.06(1H,d,J＝9.9Hz,H-7),3.12(1H,d,J＝9.9Hz,H-8),3.07(1H,br s,H-10),3.00(1H,q,J＝7.2Hz,H-11),5.28(1H,s,H-12),5.57(1H,d,J＝1.3Hz,H-14),5.00(1H,s,H-16a),5.04(1H,s,H-16b),1.88(3H,s,H 3-17),1.42(3H,d,J＝7.2Hz,H 3-18),1.73(3H,br s,H 3-19),4.09(1H,d,J＝10.9Hz,H-20a),4.39(1H,d,J＝10.9Hz,H-20b),12-OBz:7.93(2H,d,J＝7.5Hz),7.46(2H,dd,J＝7.5,7.5Hz),7.56(1H,m)；1′-Ph:7.71(2H,m),7.42(2H,m),7.41(1H,m)； 13C NMR(CDCl 3,125MHz)δ C 158.8(C-1),137.5(C-2),208.2(C-3),73.4(C-4),81.1(C-5),78.2(C-6),63.7(C-7),36.9(C-8),78.5(C-9),50.7(C-10),43.0(C-11),78.4(C-12),84.7(C-13),81.8(C-14),142.7(C-15),114.0(C-16),18.9(C-17),18.2(C-18),9.9(C-19),63.6(C-20),117.3(C-1′),1′-Ph:134.9,125.9×2,128.1×2,129.8,12-OBz:165.0,129.4,129.4×2,128.7×2,133.6；HRESIMS m/z 705.1289[M+Na] +(calcd for,C 34H 35O 10BrNa +,705.1306).
瑞香烷型二萜化合物对去势抵抗性前列腺癌细胞的抑制活性
(1)细胞培养
所有前列腺癌细胞均用含有10％小牛血清、100单位每毫升的青霉素及100g/mL链霉素的RPMI-1640培养基，培养于含5％二氧化碳的饱和湿度为37℃恒温培养箱中。
(2)细胞毒活性测试
取对数生长期的细胞于96孔板中培养24小时(5×10 3cells/well)，然后用不同浓度的待测化合物处理，用MTT法培养4小时，离心弃去上清液，加入DMSO溶解MTT结晶，以酶联免疫检测仪在570nm波长测吸光度值。用IC 50表示待测化合物对癌细胞的细胞毒活性。
(3)实验结果
如表1所示，大部分瑞香烷型二萜均表现出不同程度的抑制多种前列腺癌细胞的活性，部分代表性化合物对前列腺癌细胞的抑制活性显著，IC 50处于nM水平，强于阳性药阿霉素和恩杂鲁胺(ENZ)，其中化合物YH-11、YH-22和YH-52等活性最为突出。初步构效关系分析表明，含有9,13,14-原酸酯的化合物(YH-11和YH-52等)的抑制活性显著高于不含原酸酯的化合物(YH-56、YH-60和YH-61)，说明原酸酯为关键的药效基团。其次，20-OH被 亲酯性基团取代后会导致活性明显降低，例如化合物YH-5、YH-9、YH-12、YH-19、YH-20、YH-25等；另外，6,7-环氧被开环形成双羟基产物YH-51时活性明显降低，而开环形成溴代产物YH-52时活性增强并且对正常人前列腺细胞RWPE-1的毒性比原型化合物YH-11显著降低。该类化合物1′-烯烃侧链的修饰对活性有着不可预见的影响，但总体而言，带有1′-烯烃侧链的化合物细胞毒性更强，例如化合物YH-16和YH-22细胞毒性强于YH-11和YH-6。YH-52被选为候选化合物进行动物体内药效学评价。
表1代表性瑞香烷型二萜化合物对几种人前列腺癌细胞及正常细胞的抑制活性
Figure PCTCN2021116955-appb-000019
Figure PCTCN2021116955-appb-000020
ENZ：阳性药恩杂鲁胺；DOX：阳性药阿霉素；NA：活性较低，未测试。
化合物YH-52动物体内药效学评价
(1)小鼠22RV1前列腺癌生长模型的构建
首先大量扩增22RV1细胞，为保证荷瘤的成功率需把细胞状态调整到最佳状态。待细胞数量足够时，消化细胞并用PBS缓冲液洗两遍去除培养基中的胎牛血清(FBS)以减少免疫排斥反应。血球计数板计数后将细胞调整到3000*10 4/mL。然后将22Rv1人前列腺癌细胞(100μL)皮下注射到4-5周龄的nod-scid重症免疫缺陷雄性小鼠。
(2)分组及给药
口服给药实验：
待肿瘤长到100mm 3体积左右时，将小鼠分随机为3组(平均肿瘤体积相同)，加药组小鼠每天口服灌胃0.5mg/kg及2mg/kg的化合物YH-52，对照组给予同样体积DMSO含量的生理盐水。每3天测量并记录小鼠体重及肿瘤的长与宽，持续给药的时间如图2所示，待实验结束后取皮下肿瘤，拍照。按照公式体积＝长×宽 2×π/6计算，统计肿瘤体积。
联合恩杂鲁胺腹腔注射给药实验:
待肿瘤长到100mm 3左右时，将小鼠分随机为4组(平均肿瘤体积相同)，加药组小鼠每天腹腔注射0.1mg/kg的化合物YH-52，阳性药组小鼠每天腹腔注射10mg/kg的恩杂鲁胺，联合用药组小鼠每天同时腹腔注射0.1mg/kg的化合物YH-52和10mg/kg恩杂鲁胺，对照组给予同样体积DMSO含量的生理盐水。每3天测量并记录小鼠体重及肿瘤的长与宽，持续给药的时间如图3所示，待实验结束后取皮下肿瘤，拍照。按照公式体积＝长×宽 2×π/6计算，统计肿瘤体积。
(3)实验结果
如图2所示，化合物YH-52可以在口服灌胃0.5mg/kg和2mg/kg剂量下明显抑制小鼠肿瘤的生长。与阳性药恩杂鲁胺(ENZ)比较，YH-52腹腔注射给药(剂量0.1mg/kg)表现出更强的疗效，并且在0.1mg/kg剂量下联合恩杂鲁胺(10mg/kg)腹腔注射给药有明显的协同增效(图3)。
可以预见，化合物药学上可接受的盐，可以产生相同或相近的活性。

Claims (12)

  1. 瑞香烷型二萜化合物在制备去势抵抗性前列腺癌治疗或联合治疗药物中的应用，其特征在于：所述瑞香烷型二萜化合物的通式如式Ⅰ或式II所示：
    Figure PCTCN2021116955-appb-100001
    式I和式II中：C-1和C-2之间为双键或不为双键；C-6和C-7之间为双键或不为双键；C-15和C-16之间为双键或不为双键；
    R 1选自氢或羟基；
    R 2选自氢、羟基、羰基、苯甲酰基或乙酰基；
    R 3选自氢、羟基、乙酰基、异戊酰基、巴豆酰基或苯甲酰基；
    R 4选自氢、羟基、乙酰基、异丁酰基、2-噻吩甲酰基、苯甲酰基或棕榈酰基；
    R 5选自羟基、氟、氯、溴、碘，与R 6形成三元环氧或与R 6消除形成C6＝C7双键；
    R 6选自氢、羟基、氟、氯、溴、碘，与R 5形成三元环氧或与R 5消除形成C6＝C7双键；
    式I中：R 7选自甲基、苯基、壬烷基、(1E，3E)-壬二烯基、(1E，3Z)-壬二烯基或(1E，3E，5E)-壬三烯基；
    式II中：R 7选自氢、苯甲酰基、乙酰基、癸酰基、(2E，4E)-癸二烯酰基、(2E，4Z)-癸二烯酰基或(2E，4E，6E)-癸三烯酰基；
    R 8选自氢或羟基；
    R 9选自氢、羟基、乙酰基、苯甲酰基、异丁酰基、丁酰基或丙酰基。
  2. 根据权利要求1所述的应用，其特征在于：所述瑞香烷型二萜化合物选自：
    Figure PCTCN2021116955-appb-100002
  3. 根据权利要求2所述的应用，其特征在于：所述瑞香烷型二萜化合物选自YH-6、YH-11、YH-16、YH-17、YH-22、YH-35、YH-36、YH-47、YH-48、YH-49、YH-50、YH-52及YH-53中的至少一种。
  4. 根据权利要求1或2所述的应用，其特征在于：所述瑞香烷型二萜化合物还包括其药学上可接受的衍生物。
  5. 根据权利要求4所述的应用，其特征在于：所述药学上可接受的衍生物为其盐。
  6. 瑞香烷型二萜化合物及其药用衍生物，其特征在于：所述瑞香烷型二萜化合物如权利要求1所述。
  7. 根据权利要求6所述的瑞香烷型二萜化合物及其药用衍生物，其特征在于：所述瑞香烷型二萜化合物选自权利要求2中的化合物YH-8、YH-9、YH-10、YH-19、YH-20、YH-21、YH-24、YH-25、YH-26、YH-30、YH-33、YH-34、YH-37、YH-38、YH-39、YH-45、YH-46、YH-47、YH-48、YH-49、YH-50、YH-52、YH-53、YH-56、YH-57、YH-60、YH-61。
  8. 一种治疗或辅助治疗去势抵抗性前列腺癌的组合物，其特征在于：所述组合物的活性成分包括权利要求1～5任一项所述的瑞香烷型二萜化合物及其可接受的药用衍生物中的至少一种。
  9. 根据权利要求8所述的组合物，其特征在于：所述瑞香烷型二萜化合物选自权利要求2中的化合物YH-6、YH-11、YH-16、YH-17、YH-22、YH-35、YH-36、YH-8、YH-9、YH-10、YH-19、YH-20、YH-21、YH-24、YH-25、YH-26、YH-30、YH-33、YH-34、YH-37、YH-38、YH-39、YH-45、YH-46、YH-47、YH-48、YH-49、YH-50、YH-52、YH-53、YH-56、YH-57、YH-60、YH-61及其可接受的药用衍生物。
  10. 根据权利要求8所述的组合物，其特征在于：所述组合物还包括至少一种对前列腺癌有治疗作用的化合物，优选的，所述对前列腺癌有治疗作用的化合物为恩杂鲁胺、阿比特龙、环磷酰胺、阿霉素、多烯紫杉醇、米托蒽醌。
  11. 一种治疗或辅助治疗去势抵抗性前列腺癌的方法，包括：
    检测确认患者患有势抵抗性前列腺癌；
    给予患者治疗量的瑞香烷型二萜化合物或其药学上可接受的盐、溶剂化物、共晶，所述瑞香烷型二萜化合物如权利要求1所述。
  12. 根据权利要求11所述的方法，其特征在于：还包括给予患者至少一种对前列腺癌有治疗作用的化合物，优选的，所述对前列腺癌有治疗作用的化合物为恩杂鲁胺、阿比特龙、环磷酰胺、阿霉素、多烯紫杉醇、米托蒽醌。
PCT/CN2021/116955 2020-12-22 2021-09-07 一类抗前列腺癌的瑞香烷型二萜及其制备方法 WO2022134657A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US18/157,529 US20230159551A1 (en) 2020-12-22 2023-01-20 Daphnane diterpenoid resistant to prostate cancer and preparation method thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202011524327.0 2020-12-22
CN202011524327.0A CN112538088B (zh) 2020-12-22 2020-12-22 一类抗前列腺癌的瑞香烷型二萜及其制备方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/157,529 Continuation-In-Part US20230159551A1 (en) 2020-12-22 2023-01-20 Daphnane diterpenoid resistant to prostate cancer and preparation method thereof

Publications (1)

Publication Number Publication Date
WO2022134657A1 true WO2022134657A1 (zh) 2022-06-30

Family

ID=75019503

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/116955 WO2022134657A1 (zh) 2020-12-22 2021-09-07 一类抗前列腺癌的瑞香烷型二萜及其制备方法

Country Status (3)

Country Link
US (1) US20230159551A1 (zh)
CN (1) CN112538088B (zh)
WO (1) WO2022134657A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112538088B (zh) * 2020-12-22 2022-02-22 中山大学 一类抗前列腺癌的瑞香烷型二萜及其制备方法
CN116120334A (zh) * 2022-11-10 2023-05-16 沈阳药科大学 芫花花蕾中的二萜类化合物及其制备方法和应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009096655A1 (en) * 2008-01-31 2009-08-06 Ewha University-Industry Collaboration Foundation Composition comprising the compound isolated from the flower extract of daphne genkwa for preventing and treating cancer disease and the use thereof
CN101531644A (zh) * 2009-02-18 2009-09-16 沈阳药科大学 芫花中新的瑞香烷型二萜类化合物及其制备方法和用途
CN102344455A (zh) * 2011-08-13 2012-02-08 中国科学院昆明植物研究所 瑞香烷型二萜原酸酯类化合物，其药物组合物及其制备方法和应用
KR20140015798A (ko) * 2012-07-25 2014-02-07 서울대학교산학협력단 다프난 다이터페노이드（Ｄａｐｈｎａｎｅ ｄｉｔｅｒｐｅｎｏｉｄ）계 물질의 상피세포 성장인자 수용체（ＥＧＦＲ） 저해제인 제피티닙（Ｇｅｆｉｔｎｉｂ） 내성 인간 폐암 세포에 유용한 항암제
CN108689851A (zh) * 2018-05-28 2018-10-23 中山大学 一类惕各烷型二萜化合物及其制备方法和应用
CN111410679A (zh) * 2020-03-19 2020-07-14 上海市第七人民医院 Daphnane型大环二萜类化合物制备及应用
CN112538088A (zh) * 2020-12-22 2021-03-23 中山大学 一类抗前列腺癌的瑞香烷型二萜及其制备方法
CN112920196A (zh) * 2021-01-29 2021-06-08 中山大学 一类抗肥胖症的瑞香烷型二萜及其应用

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009096655A1 (en) * 2008-01-31 2009-08-06 Ewha University-Industry Collaboration Foundation Composition comprising the compound isolated from the flower extract of daphne genkwa for preventing and treating cancer disease and the use thereof
CN101531644A (zh) * 2009-02-18 2009-09-16 沈阳药科大学 芫花中新的瑞香烷型二萜类化合物及其制备方法和用途
CN102344455A (zh) * 2011-08-13 2012-02-08 中国科学院昆明植物研究所 瑞香烷型二萜原酸酯类化合物，其药物组合物及其制备方法和应用
KR20140015798A (ko) * 2012-07-25 2014-02-07 서울대학교산학협력단 다프난 다이터페노이드（Ｄａｐｈｎａｎｅ ｄｉｔｅｒｐｅｎｏｉｄ）계 물질의 상피세포 성장인자 수용체（ＥＧＦＲ） 저해제인 제피티닙（Ｇｅｆｉｔｎｉｂ） 내성 인간 폐암 세포에 유용한 항암제
CN108689851A (zh) * 2018-05-28 2018-10-23 中山大学 一类惕各烷型二萜化合物及其制备方法和应用
CN111410679A (zh) * 2020-03-19 2020-07-14 上海市第七人民医院 Daphnane型大环二萜类化合物制备及应用
CN112538088A (zh) * 2020-12-22 2021-03-23 中山大学 一类抗前列腺癌的瑞香烷型二萜及其制备方法
CN112920196A (zh) * 2021-01-29 2021-06-08 中山大学 一类抗肥胖症的瑞香烷型二萜及其应用

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BAXTER ROBERT L., ZIEGLER MYRA F.: "Antileukaemic properties of 12-hydroxydaphnetoxin derivatives", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 4, no. 22, 1 November 1994 (1994-11-01), AMSTERDAM, NL , pages 2649 - 2652, XP055945185, ISSN: 0960-894X, DOI: 10.1016/S0960-894X(01)80689-2 *
BROOKS, G. ; EVANS, A. ; AITKEN, A. ; EVANS, F.J. ; RIZK, A.F.M. ; HAMMOUDA, F.M. ; EL-MISSIRY, M.M. ; ISMAIL, S.E.: "Daphnane diterpenes of Thymelaea hirsuta", PHYTOCHEMISTRY, ELSEVIER, AMSTERDAM , NL, vol. 29, no. 7, 1 January 1990 (1990-01-01), Amsterdam , NL , pages 2235 - 2237, XP026616241, ISSN: 0031-9422, DOI: 10.1016/0031-9422(90)83044-2 *
HUANG, S.Z.;ZHANG, X.J.;LI, X.Y.;KONG, L.M.;JIANG, H.Z.;MA, Q.Y.;LIU, Y.Q.;HU, J.M.;ZHENG, Y.T.;ET AL.;: "Daphnane-type diterpene esters with cytotoxic and anti-HIV-1 activities from Daphne acutiloba Rehd.", PHYTOCHEMISTRY, ELSEVIER, AMSTERDAM , NL, 1 May 2013 (2013-05-01), Amsterdam , NL , pages 99 - 107, XP018508118, ISSN: 0031-9422, DOI: 10.1016/j.phytochem.2011.11.013 *
LI FEIFEI; SUN QIAN; HONG LILI; LI LINGZHI; WU YINGYING; XIA MINGYU; IKEJIMA TAKSHI; PENG YING; SONG SHAOJIANG: "Daphnane-type diterpenes with inhibitory activities against human cancer cell lines fromDaphne genkwa", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 23, no. 9, 15 March 2013 (2013-03-15), AMSTERDAM, NL , pages 2500 - 2504, XP028546979, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2013.03.025 *
PAN RONG-RONG, ZHANG CHUN-YAN, LI YUAN, ZHANG BING-BING, ZHAO LIANG, YE YING, SONG YA-NAN, ZHANG MIAO, TIE HONG-YUN, ZHANG HONG, Z: "Daphnane Diterpenoids from Daphne genkwa Inhibit PI3K/Akt/mTOR Signaling and Induce Cell Cycle Arrest and Apoptosis in Human Colon Cancer Cells", JOURNAL OF NATURAL PRODUCTS, AMERICAN CHEMICAL SOCIETY, US, vol. 83, no. 4, 24 April 2020 (2020-04-24), US , pages 1238 - 1248, XP055945184, ISSN: 0163-3864, DOI: 10.1021/acs.jnatprod.0c00003 *
SHIGEMORI HIDEYUKI, NAKASONE RIE, KURISU MANAMI, ONODERA MANAMI, MIYAMAE YUSAKU, MATSUURA DAISUKE, KANATANI HIROTOSHI, YANO SHINGO: "Promoting effects on hepatocyte growth factor production of daphnane diterpenoids from Daphne odora", HETEROCYCLES, vol. 87, no. 5, 31 December 2013 (2013-12-31), JP , pages 1087 - 1092, XP009537707, ISSN: 0385-5414, DOI: 10.3987/COM-13-12687 *
WANG, CHENG-RUI; CHEN, ZHENG-XIONG; YING, BAI-PING; ZHOU, BING-NAN; LIU, JIA-SEN; PAN, BEI-CHUAN: "Study on Effective Constituents of the Root of Genkwa Flower II. Isolation and Structure of a New Antifertility Vinegar b of Lilodes Genkwa", ACTA CHIMICA SINICA, vol. 39, no. 5, 31 October 1981 (1981-10-31), CN , pages 421 - 426, XP009537708, ISSN: 0567-7351 *
ZHANG, S. ; LI, X. ; ZHANG, F. ; YANG, P. ; GAO, X. ; SONG, Q.: "Preparation of yuanhuacine and relative daphne diterpene esters from Daphne genkwa and structure-activity relationship of potent inhibitory activity against DNA topoisomerase I", BIOORGANIC, ELSEVIER, AMSTERDAM, NL, vol. 14, no. 11, 1 June 2006 (2006-06-01), AMSTERDAM, NL, pages 3888 - 3895, XP027992658, ISSN: 0968-0896 *

Also Published As

Publication number Publication date
CN112538088B (zh) 2022-02-22
CN112538088A (zh) 2021-03-23
US20230159551A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
WO2022134657A1 (zh) 一类抗前列腺癌的瑞香烷型二萜及其制备方法
CA2454799C (en) Novel dammarane sapogenins, their use as anti-cancer agents, and a process for producing same
WO2012149667A1 (zh) 一类强心苷类化合物及其抗肿瘤用途
JP2010540471A (ja) ガンボギン酸グリコシド誘導体及びアナログ、並びにその製法及び応用
CN110903340B (zh) 四环三萜衍生物及其药物组合物和应用
WO2016192631A1 (zh) 具有降血脂活性的松香烷型二萜类化合物，其制备方法及用途
CN111471080B (zh) ocotillol型人参皂苷元A环并氨基噻唑环衍生物及制备方法
WO2011131102A1 (zh) 含笑内酯的制备方法及其用途
WO2017190421A1 (zh) 一种新型罗汉果醇衍生物单体
CN107216283A (zh) 一种含有二氢吡啶结构的β－榄香烯衍生物及其制备方法和用途
CN112920196B (zh) 一类抗肥胖症的瑞香烷型二萜及其应用
JP2001122871A (ja) エストロゲン様作用薬剤
WO2008031264A1 (fr) Composé de glycoside de furost-5-ène-3, 22, 26-triol pour la prévention et le traitement des cancers
CN111518157B (zh) 一种雷公藤甲素衍生物及其制备方法和应用
WO2017190419A1 (zh) 一种罗汉果醇衍生物单体及其组合物的用途
JPWO2018101434A1 (ja) グリコシル化クロリンｅ６誘導体、または、その薬学的に許容される塩、医薬組成物、標的を破壊する方法、および、グリコシル化クロリンｅ６誘導体、またはその薬学的に許容される塩の製造方法
WO2013097661A1 (zh) 呋甾烷型皂苷衍生物及其用途
CN115246868A (zh) 一类五环三萜类化合物在治疗神经退行性疾病中的用途
JP2009274956A (ja) ニーム種子由来の悪性腫瘍治療薬
CN111606917A (zh) 一种具c环骈合内酯环新颖骨架的松香烷类化合物及其制备方法与应用
KR100547253B1 (ko) 암 예방 및 치료에 유효한 진세노사이드 유도체
US5962515A (en) Process for isolation and synthesis of 1-(3,4 methylenedioxy-phenyl)-1E-tetradecene and its analogues and their activities against tumors and infections
JP2001199884A (ja) 鎮痛作用剤
US10766922B2 (en) Substituted steroids for the treatment of cancer
JP2005314236A (ja) 新規クアシノイド系化合物及びそれらの用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21908660

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21908660

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 21908660

Country of ref document: EP

Kind code of ref document: A1